Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Adult Leukemias

20 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCHEM1305

04/02/2013

Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Basic Science

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Diagnostic

ECOGHEMEAI141

05/10/2016

Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

Other

VICCHEM14133

11/11/2015

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Supportive Care

VICCBMT15101

01/22/2016

A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute Graft-Versus-Host Disease

Supportive Care

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Treatment

VICCHEM15113

05/06/2016

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

Treatment

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

VICCPED1537

04/28/2016

T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Treatment

VICCHEM1553

03/10/2016

Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML

Treatment

VICCHEM1597

02/17/2016

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Treatment

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCHEM1508

08/20/2015

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Treatment

VICCBMT1406

06/29/2015

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

Treatment

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

VICCHEM1505

05/06/2015

An Open-Label Phase I Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1143572 given in a Once-Daily or an Intermittent Dosing Schedule in Subjects with Advanced Acute Leukemia

Treatment

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment

VICCHEM1294

02/25/2013

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Treatment

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum